Coronary Insufficiency | Page 2 of 4 | Links Medicus Content Curation & Alerts in Medicine

Interrupting DAPT after 1 month post PCI:
Meta-analysis of 4 RCTs, >25000 pts
Events between 31days and 1yr:
Less bleeding (1.1 vs 1.5%) but no difference in death (1.3 vs 1.6%), MI (1.4 vs 1.2%), ST (0.3 vs 0.2%) or stroke (0.5 vs 0.6%) https://t.co/rdNgCg032B #cardiotwitter pic.twitter.com/yLWREcDzYe

— Heeraj Bulluck (@DrHBulluck) October 30, 2022

Under a http://creativecommons.org/licenses/by/4.0/ license

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

1 Nov, 2022 | 12:02h | UTC

Severity of obstructive coronary artery stenosis after pre-eclampsia – Heart

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease.

26 Oct, 2022 | 14:27h | UTC

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease – Age and Ageing

M-A | Coronary perforation incidence, outcomes and temporal trends.

24 Oct, 2022 | 14:10h | UTC

Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis – openheart

M-A | The optimal timing for non-culprit PCI in patients with multivessel coronary artery disease.

21 Oct, 2022 | 12:52h | UTC

The optimal timing for non-culprit percutaneous coronary intervention in patients with multivessel coronary artery disease: A pairwise and network meta-analysis of randomized trials – Frontiers in Cardiovascular Medicine

Cohort Study | 3-year outcomes of patients with spontaneous coronary artery dissection.

19 Oct, 2022 | 14:23h | UTC

Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Spontaneous Coronary Artery Dissection: Lower Than Expected Recurrence Rate in a Large Prospective Canadian Cohort – Journal of the American College of Cardiology

Commentary: SCAD Heart Attacks: Outcomes Not as Bad as Previously Feared – Daytonews

Position Statement | Use of biomarkers for the management of heart failure and acute coronary syndrome.

17 Oct, 2022 | 12:34h | UTC

Saudi Heart Association Position Statement on the Use of Biomarkers for the Management of Heart Failure and Acute Coronary Syndrome – Journal of the Saudi Heart Association

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Commentary on Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Under a Creative Commons Attribution (CC BY 4.0) License

Review | Therapeutic management of anomalous coronary arteries originating from the opposite sinus of Valsalva.

11 Oct, 2022 | 13:32h | UTC

Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the Unknowing – Journal of the American Heart Association

Commentary from the author on Twitter

Hot off the press?: happy to share our review in @JAHA_AHA highlighting the management of #ACAOS #AAOCA considering pathophysiology and hemodynamics. @biglermarius @MassimoPadalin3 @MatthiasSiepe @RaberLorenz https://t.co/25hRZlj9wR pic.twitter.com/3F1Oqucq7G

— Christoph Gräni (@chrisgraeni) October 8, 2022

Under a Creative Commons Attribution‐NonCommercial License

M-A of randomized trials | Colchicine and coronary heart disease risks.

3 Oct, 2022 | 14:00h | UTC

Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials – Frontiers in Cardiovascular Medicine

M-A: Colchicine after percutaneous coronary intervention significantly reduces the risk of major adverse cardiovascular events in patients with symptomatic coronary artery disease.

Expert Analysis | Colchicine in acute coronary syndrome: when to commence?

M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.

Review: Colchicine and the heart.

M-A: Colchicine administration for percutaneous coronary intervention

M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease

Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease

#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome

#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

#AHA19 – [Abstract Only] Practice Changing? – Randomized Trial: Low-Dose Colchicine Improves Outcomes after Myocardial Infarction

Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome

Long-term follow-up of a RCT | P2Y12 inhibitor monotherapy vs. DAPT after percutaneous coronary intervention.

3 Oct, 2022 | 13:58h | UTC

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)

Original Study: Randomized Trials: Shorter Duration of Dual Antiplatelet Therapy May be an Option for Patients Undergoing Percutaneous Coronary Intervention

Commentary on Twitter

In #RCT follow-up, P2Y12 inhibitor monotherapy after 3 months of DAPT found to be comparable with prolonged DAPT for preventing ischemic events. P2Y12 inhibitor monotherapy resulted in significantly lower rate of major bleeding for up to 3 yrs. https://t.co/pBv9X87lEg #Research pic.twitter.com/42Y28hPPT2

— JAMA Cardiology (@JAMACardio) September 30, 2022

Study | Plaque histology and myocardial disease in sudden coronary death.

30 Sep, 2022 | 12:41h | UTC

Plaque histology and myocardial disease in sudden coronary death: the Fingesture study – European Heart Journal

RCT | Abbreviated antiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk.

29 Sep, 2022 | 13:32h | UTC

Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk – Journal of the American College of Cardiology

Original publication: #ESCCongress – RCT: In patients who underwent PCI at high bleeding risk, 1 month of dual antiplatelet therapy was noninferior to the continuation of dual therapy for at least 2 additional months and resulted in a lower incidence of bleeding events.

RCT | Routine pressure wire assessment vs. conventional angiography in patients with coronary artery disease.

27 Sep, 2022 | 13:19h | UTC

Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial – Circulation

RCT: In patients with multivessel coronary artery disease, a Fractional Flow Reserve (FFR) guided revascularization strategy did not reduce the risk of ischemic cardiovascular events or death at 1-year follow-up compared to a traditional strategy without FFR.

RCT: In patients with three-vessel coronary artery disease, an FFR–guided PCI strategy was NOT noninferior to coronary bypass surgery – The 1-year incidence of the composite primary end point (death, myocardial infarction, or stroke) was 7.3% in the FFR-guided PCI group and 5.2% in the CABG group.

#ACC21 – RCT: In patients with STEMI undergoing complete revascularization, an FFR-guided strategy did not improve outcomes compared to an angiography-guided strategy.

Cohort Study | Incidence and outcomes of coronary artery perforations.

27 Sep, 2022 | 13:09h | UTC

Coronary Artery Perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study – Journal of the American Heart Association

Cohort Study | Association of high‐sensitivity Troponin T and I with mortality and cardiovascular outcomes in stable patients.

26 Sep, 2022 | 11:59h | UTC

Association of High‐Sensitivity Troponin T and I Blood Concentrations With All‐Cause Mortality and Cardiovascular Outcome in Stable Patients—Results From the INTERCATH Cohort – Journal of the American Heart Association

Invited Commentary: Troponin in Stable Patients Undergoing Coronary Angiography: Should It Be Routinely Assessed? – Journal of the American Heart Association

RCT | Effect of clinical decision support with audit and feedback on prevention of acute kidney injury in patients undergoing coronary angiography.

22 Sep, 2022 | 13:04h | UTC

Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Intervention Cuts Risk for AKI After Coronary Angiography – HealthDay

Commentary on Twitter

This multifaceted intervention led to a lower risk of acute kidney injury in patients undergoing coronary angiography, percutaneous coronary intervention, or both. #Research https://t.co/rKVBsRxHy7

— JAMA (@JAMA_current) September 7, 2022